Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of “Moderate Buy” by Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $6.8750.

A number of research analysts have commented on the company. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Friday, July 17th.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the business. Greenline Wealth Management LLC acquired a new stake in Sensus Healthcare during the fourth quarter worth approximately $513,000. Rothschild Wealth LLC bought a new position in shares of Sensus Healthcare in the fourth quarter worth $500,000. North Star Investment Management Corp. acquired a new position in Sensus Healthcare in the first quarter valued at about $500,000. Pacific Ridge Capital Partners LLC grew its stake in Sensus Healthcare by 21.8% during the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after buying an additional 125,245 shares in the last quarter. Finally, Ingalls & Snyder LLC bought a new position in Sensus Healthcare in the 4th quarter valued at about $219,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $2.85 on Thursday. The firm has a market cap of $46.91 million, a P/E ratio of -6.06 and a beta of 1.09. Sensus Healthcare has a 52 week low of $2.66 and a 52 week high of $5.92. The firm’s 50-day simple moving average is $2.95 and its 200 day simple moving average is $3.81.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The firm had revenue of $3.39 million for the quarter, compared to the consensus estimate of $5.32 million.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.